- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Copay Assistance Programs for Adalimumab Biosimilars
Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
The conversation delves into the experience with copay assistance programs for biosimilars, highlighting the need for effective patient support to ensure broad uptake and continued adherence. Participants note the familiarity with existing programs for originator drugs and stress the importance of replicating similar support systems for biosimilars to maintain patient confidence.
Concerns arise regarding gaps in education and communication from biosimilar manufacturers, emphasizing the necessity of comprehensive support programs and clear communication channels. Patient access to biosimilars is seen as crucial, with biosimilar adoption programs needing to address various factors such as coverage, support systems, and pharmacoeconomic considerations.
The discussion underscores the significance of accessible and efficient support systems, both for insured and uninsured patients, to facilitate biosimilar adoption. Additionally, effective communication among healthcare providers, specialty pharmacists, and patients is highlighted as essential for navigating access to these programs and ensuring optimal patient care.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Not So Different: Dr Gary Lyman Explains How to Ensure Physician Confidence in Biosimilars
August 15th 2021Gary Lyman, MD, MPH, an oncologist and hematologist, discusses some of the issues holding physicians back from prescribing biosimilars and some ways to ensure provider confidence in biosimilars.
Comparable Safety, Efficacy Between First Proposed Natalizumab Biosimilar, Reference for MS
March 3rd 2023Phase 3 study findings support a proposed natalizumab biosimilar (PB006) as the first biosimilar alternative to reference natalizumab (Tysabri) for treatment of relapsing-remitting multiple sclerosis (MS).
Denosumab Biosimilar Demonstrates Noninferiority to Prolia in Postmenopausal Osteoporosis
July 30th 2022Results from a phase 3 trial suggested similar efficacy and safety of the denosumab biosimilar candidate Arylia (AryoGen Pharmed) to the reference product (Prolia) in postmenopausal osteoporosis.
